Review Article

Open Access

An Overview of an Invasive Fungal Infection In Covid-19: Mocormycosis

Himanshu¹ and Mukesh kumar^{2*}

¹Bachelor of Pharmacy, NGI College of Pharmacy, NGI Campus, NH-58, Near Sardar Vallabh Bhai Patel Agriculture University, Modipuram, Meerut, 250110, Uttar Pradesh, India

²Department of Pharmacy, Kharvel Subharti College of Pharmacy, SVSU, Subhartipuram NH-58, Delhi-Haridwar Bypass Road, Meerut, Uttar Pradesh 250005 India

ABSTRACT

Mocormycosis is an invasive fungal infection of zygomycetes class, comprised the orders of entomophtherales and mucorales which is common infection in immuno compromised patients, especially in stem cell transplantation, hematological malignancy and diabetes mellitus. It is the third invasive fungal infection after aspergillosis and candidiasis both strain belong the class of zygomycetes. Mocormycosis generally transmitted in humans by the inoculation and inhalation of spores in mucous membrane as well as skin. After the deadly outbreak of corona virus, this infection has taken a different form in those patients who suffer from the covid-19 which is categorized as a post covid-19 disease. Aim of this review to highlight the recent awareness about invasive fungal treatment.

*Corresponding author

Mukesh Kumar, Department of Pharmacy, Kharvel Subharti College of Pharmacy, SVSU, Subhartipuram NH-58, Delhi-Haridwar Bypass Road, Meerut, Uttar Pradesh 250005 India. Tel: +918954905851; E mail: mukeshkumarrks21@gmail.com

Received: July 22, 2021; **Accepted:** July 30, 2021; **Published:** July 31, 2021

Keywords: Mocormycosis, Covid-19, Fungal infection

Introduction

At the end of December 2019, a deadly outbreak of corona virus occurred in Wuhan, China which spread rapidly in all over the world. With the help of exploitation of sequence technology corona virus disease gets a discontinuous identification commonly known as corona virus disease 2019 and the etiological agent was elucidated as Severe acute respiratory syndrome. COVID-19 or SARS-CoV-2 generally spread or transmit via respiratory droplets between human-to-human and it also consisting different types of symptoms such as pharyngitis, sternutation, cold, headache, tightness etc [1]. If we concern about the current status of weekly epidemiological update of covid-19 given by world health organization till end of June 3rd 3 million cases were reported in a week with 60 thousand mortality rate which is shown in (Table 1).

Table 1: Reported cumulative COVID-19 confirmed cases and mortality rate as per world health organization

WHO Region	New cases in last 7 days (%)	Changes in new cases in last 7 days	Cumulative cases (%)	New deaths in last 7 days (%)	Change in new deaths in last 7 days	Cumulative deaths (%)
America	1173561 (36%)	-5%	53937714 (44%)	31040 (51%)	2%	1299243 (48%)
Europe	1441065 (44%)	13%	4251672 (35%)	21772 (36%)	1%	929332 (34%)
South-East Asia	298438 (9%)	49%	14182826 (12%)	2435 (4%)	14%	214790 (8%)
Eastern Mediterranean	263650 (8%)	8%	7124121 (6%)	3253 (5%)	12%	153446 (6%)
Africa	50916 (2%)	-3%	2999152 (2%)	1428 (2%)	10%	76113 (3%)
Western Pacific	63730 (2%)	29%	1775560 (1%)	486 (1%)	-33%	30843 (1%)
Global	3291360 (100%)	8%	122536880 (100%)	60414 (100%)	3%	2703780 (48%)

Mucormycosis and zygomycosis is an invasive fungal infection belonging to the order mucorales generally caused by a group of molds called mucormycetes [2]. Mucormycosis is the second frequent invasive mold disease after aspergillosis. Patients have higher risk who suffers from poorly controlled diabetes mellitus, those who undergoing the treatment of hematopoietic stem cell transplantation, treatment of hematological cancer and who have sustained severe trauma to soft tissues [3]. These types of conditions referred as black fungus. As per the survey that mucormycosis is rising in post covid-19 patients and it comes when the patients having low immunity power and have been wearing a mask which is used in multiple times, it will absorbed humidity by the process of inhalation and exhalation and will get a proper atmosphere to grow fungus [4].

History

An American pathologist R.D Baker coined the term mucormycosis for the first time which is also known as zygomycosis. It is defined as an invasive fungal infection caused by mucorales and the number of zygomycotic species [5]. Mucormycotina are the common example of saprobes which originates from soil or decaying matter. In 1885, the German pathologist Paltauf reported the first case of mucormycosis and it was accrescent seen between the immuno compromised individuals during 1980s and 1990s [6]. According to the proliferation rate, a case study carried out in France which reported 7.4% amplification per year and worldwide occurrence has been reported along with mucorales infection with the possibilities of their seasonal variation [7, 8].

Microbiology

Fungi belong to order mucorales which differentiate into six categories i.e. Mucoraceae, Cunninghamellaceae, Syncephalastraceae, Saksenaceae, Mortierellaceae and Thamnidaceae shown in (Table 2).

Table 2: Classification of the Etiological agents responsible for mucormycosis

Sr. No.	Family	Genus	Species
1	Mucoraceae	Absidia	A. Corymbifera
		Apophysomyces	A. elegans
		Mucor	M. circinelloides
			M. hiemalis
			M. racemosus
			M. ramosissimus
			M. rouxianus
		Rhizopus	R. pusillus
			R. arrhizus
			R. azygosporus
2	Cunninghamellaceae	Cunninghamella	C. bertholletiae
3	Mortierellaceae	Mortierella	
4	Saksenaceae	Saksenaea	S. vasiformis
5	Syncephalastraceae	Syncephalastrum	S. racemosum
6	Thamnidaceae	Cokeromyces	C. recurvatus

Mucorales can be grows in both selective and non-selective media. It grows rapidly and just takes few takes with mycelia elements expanding to cover the entire plate. The mycelium is fibrous and 'cotton candy like' in appearance and its growth is so vigorous that the group demonstrated as lid filter. Recognition of the agents

is amenable for mucormycosis is based on their microscopic and macroscopic morphological criteria, carbohydrate assimilation and optimum temperature which are favorable for its growth [9]. Macroscopic criteria are accessory in establishing a presumptive identification which is confirmed by microscopic dissection after staining[10].

Crucial macroscopic characteristics are vigorous growth, hyaline appearance, light coloration on the other side of the plate (tan to yellow for more species) and variable degree of coloration on the sporulating surface of the colonies (from pure white to tan, gray, brown or even black) [11]. The family Mucoraceae can be categorized on the basis of their morphology of the predominant asexual spore producing structures (sporangia producers, sporangium producers and merosporangium producers) [12]. Species can be disassembled by elements such as rhizoids, columella and stolons which are ordinarily visualized in the microbiology laboratory on lactophenol cotton blue slides [13]. Hypae are wide, non-septate and measures 10-20 µm in diameter, with branches which is separated from the main body nearly at 90° angles shown in (Figure 1).

Figure 1: Macroscopic appearance of a positive culture for mucorales

Risk Factors

Most of the patients with invasive mucormycosis have several underlying diseases that are both predispose and influence the clinical presentation. The most common underlying diseases are [14].

- Diabetes mellitus
- Hematopoietic cell transplantation
- Hematologic malignancies
- AIDS
- Solid organ transplantation
- Iron overload
- Malnutrition
- Trauma and burns

Pathogenesis

Mucorales strikes on the deep tissues through the inhalation of airborne spores, percutaneous inoculation or ingestion. They settle a high number of patients but don't inevitably cause invasion [15]. Once the spores have perforated to subcutaneous tissues or lungs, they are converging by the first line of safeguard, mononuclear and polynuclear phagocytes. The phagocytes are able to kill the spores of mucorales in the host by generating oxidative metabolites [16]. There is a high risk of mucormycosis for those who are severely immune compromised neutropenic patients and those with phagocyte dysfunction e.g. hyperglycemia. Ketoacidosis

decreases the agitation of these phagocytes as regards the source of infection and their competence for lysis by oxidative and non-oxidative mechanism [17]. High concentration of iron in the serum is another risk-factor for mucormycosis. Patients treated with deferoxamine have a high instance of mucormycosis. Perhaps, because mucorales use this chelant as a siderophore to get more iron [18]. It is well-known that delivering of deferoxamine or iron to the animals infected with mucorales reduces the survival rate and the higher risk of mucormycosis in patients with ketoacidosis may also be due to the release of iron bound to proteins [19] If the phagocytes are escaped by the spores, they can invade vessels, in part by effective adherence to the endothelial cells ability that *Rhizopus oryzae* preserves even when the fungus is not viable [20].

Symptoms

These are the various signs and symptoms in mucormycosis such as fever, swelling over the nose and eye, headache, shortness of breath, vomiting, cough, abdominal pain, skin swelling, skin redness, bloody vomit, skin redness, dark scabbing in the nose etc [21]. Graphical representations of mucormycosis symptoms was shown in (Figure 2).

Figure 2: Graphical representations of mucormycosis symptoms

Diagnosis

Diagnosis of mucormycosis comprises cautious evaluation of clinical manifestations utilization of computed tomography, magnetic resonance imaging modalities, finest application of clinical microbiological technique, and specialist assessment of cytological and histological provision and execution of molecular detection. Investigation of host factors allow considerably to the estimation of a patients possibility for an invasive fungal infection known as mucormycosis. PAS stains, histopathological examination, direct culture examinations are the various types of laboratory techniques for detecting mucormycosis [22].

Treatment

Mucormycosis treated by using antifungal drugs usually isavuconazole, posaconazole and Amphotericin-B-B and some other drugs are not effective against the fungi which cause mucormycosis such as voriconazole, fluconazole and echinocandins [23-27] Antifungal strategic for mucormycosis shown in (Table 3).

Table 3: Antifungal strategic for mocormycosis treatment

Therapy	Antifungal	Pors	Cons
Established therapies	Amphoteriocin-B-B deoxycholate (AmB)	50 years experience Toxicity cidal	Toxicity
	Liposomal Amphoteriocin-B-B (LAmB)	Less toxic than AmB Improved CNS penetration High-dose LAmB (15 mg/kg/day) superior to AmB (1 mg/kg/day) in murine model Superior to AmB in retrospective clinical study	Resistance seen in individual isolates Most expensive polyene
	Amphoteriocin-B B lipid complex (ABLC)	Less toxic than AmB	Inferior CNS penetration vs. LAmB in one rabbit study Not superior to placebo or AmB in murine model even at high doses (up to 30 mg/kg/day) No comparative clinical data published
Investigational/adjunctive therapies	Itraconazole	Superior toxicity profile Successful case reports	Poor activity in animal models despite in vitro susceptibility Breakthrough mocormycosis described during prophylactic itraconazole
	Posaconazole	More effective than itraconazole in animal models Successful case reports Possible combination with polyene therapy, but no data available	Not yet FDA approved Static in vitro Activity inferior to AmB in murine Models
	Caspofungin	Very low toxicity Synergistic with ABLC in murine model FDA approved (not for mocormycosis)	Virtually no clinical data for mocormycosis Minimal activity as mono therapy in murine model
	Iron chelation	Theoretical benefit in combination with antifungal	No data available No effective agents are FDA approved
	Hyperbaric oxygen	Nontoxic Successful case reports	Not widely available No controlled studies
	Cytokine therapy	In vitro activity Successful case reports	Limited data Expensive Toxicity profile unclear

Preventions

There are some necessary precaution against the mocormycosis such as [28-29].

- Use face mask if you are visiting any construction sites
- Maintain personal hygiene.
- Wear shoes, long sleeve shirts, long trousers and gloves during gardening
- Mocormycosis can be managed by controlling diabetes, reducing the quantity of steroids and discontinuing immunomodulating drugs.
- Control hyperglycemia.
- Monitoring the blood glucose level at particular time interval.
- Take antifungal and antibiotics judiciously

Prognosis

Prognosis generally depends on the limitation of demonstration of the disease and emphatic treatment begins in the response to the diseases. The survival rate of rhino-cerebral disease in patients without systemic disease is near about 75% with other disease is near about 20% and in pulmonary disease it is contemplated to be fatal [30]. Survival rate varies with foci of the infection: cerebral mocormycosis-45%, pulmonary forms-36%, focal cerebral mocormycosis-33%, cutaneous isolated-90%, sinusitis without cerebral involvement-87%, disseminated disease-16% and involvement of gastro intestinal form-10%. Preferable survival rate can be instated in patients with low baseline serum concentration of iron/ferritin, malignant cases and neutropenia which is not associated with infection [31].

Conclusion

In today's era mucormycosis or black fungus is a life threatening invasive fungal infection which becomes a very serious problem in all over the world after the deadly outbreak of corona virus. According to the prospective surveillance among 16,808 transplant recipients featured in 23 institutions during 2001-2006 found that mucormycosis was the extreme usual type of invasive fungal infection in stem cell recipients and accounted for 8% of all invasive fungal infection and a review of published it found an overall cause mortality rate of 54%. The mortality rate varied on the basis on the underlying patient condition which affected the body sites by the various types of fungus. The way out of this disease is, if someone found the symptoms which show a disease like mucormycosis then contact to the physicians and health care providers to tackle this terrible disease and take those precautions which are helpful for us to fight against this disease.

References

1. Van Der Hoek L, Pyrc K, Jebbink MF, Vermeulen-Oost W, Berkhout RJ, et al. (2004) Identification of a new human coronavirus. *Nature medicine*. 10: 368-373.
2. Kerbaul F, Guidon C, Collart F, Hubert Lépidi, Bruno Cayatte et al. (2004) Abdominal wall mucormycosis after heart transplantation. *J Cardiothorac Vasc Anesth*. 18: 822-823.
3. Becker BC, Schuster FR, Ganster B, Seidl HP, Schmid I, et al. (2006) Cutaneous mucormycosis in an immunocompromised patient. *Lancet Infect Dis* 6: 536.
4. Walsh TJ, Gamaletsou MN, McGinnis MR, Hayden RT, Kontoyiannis DP et al. (2012) Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary and disseminated mucormycosis (zygomycosis). *Clin Infect Dis*. 54: S55-S60.
5. Kwon-Chung KJ (2012) Taxonomy of fungi causing mucormycosis and entomophthoromycosis (zygomycosis) and nomenclature of the disease: molecular mycologic perspectives. *Clinical Infectious Diseases* 54(suppl_1): S8-15.
6. Mohammadi R, Nazeri M, Sayedayn SM, Ehteram H. A successful treatment of rhinocerebral mucormycosis due to *Rhizopus oryzae*. *Journal of research in medical sciences: The Official Journal of Isfahan University of Medical Sciences*, 2014; 19(1): 72.
7. Petrikos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, et al. (2012) Epidemiology and clinical manifestations of mucormycosis. *Clinical Infectious Diseases*. 54: S23-34.
8. McNulty JS (1982) Rhinocerebral mucormycosis: predisposing factors. *Laryngoscope* 92: 1140.
9. Lee FY, Mossad SB, Adal KA (1999) Pulmonary mucormycosis: the last 30 years. *Arch Intern Med*. 159: 1301.
10. Ismail MH, Hodgkinson HJ, Setzen G, C Sofianos, M J Hale, et al. (1990) Gastric mucormycosis. *Trop Gastroenterol*. 11: 103.
11. Adam RD, Hunter G, DiTomasso J, Comerchi G Jr (1994) Mucormycosis: emerging prominence of cutaneous infections. *Clin Infect Dis*. 19: 67.
12. Cocanour CS, Miller-Crotchett P, Reed RL 2nd, P C Johnson, R P Fischer, et al. (1992) Mucormycosis in trauma patients. *J Trauma*. 32: 12.
13. Levy E, Bia MJ (1995) Isolated renal mucormycosis: case report and review. *J Am Soc Nephrol*. 5: 2014.
14. Prabhu RM, Patel R (2004) Mucormycosis and entomophthoromycosis: a review of the clinical manifestations, diagnosis and treatment. *Clin Microbiol Infect*. 10: 31-47.
15. Waldorf AR (1989) Pulmonary defense mechanisms against opportunistic fungal pathogens. *Immunol Ser*. 47: 243-271.
16. Chinn RY, Diamond RD (1982) Generation of chemotactic factors by *Rhizopus oryzae* in the presence and absence of serum: relationship to hyphal damage mediated by human neutrophils and effects of hyperglycemia and ketoacidosis. *Infect Immun*. 38: 1123-1129.
17. Boelaert JR, de Locht M, Van Cutsem J, V Kerrels, B Cantinieaux, et al. (1993) Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. *J Clin Invest*. 91: 1979-1986.
18. Abe F, Inaba H, Katoh T, Hotchi M (1990) Effects of iron and desferrioxamine on *Rhizopus* infection. *Mycopathologia*. 110: 87-91.
19. Ribes JA, Vanover-Sams CL, Baker DJ (2000) Zygomycetes in human disease. *Clin Microbiol Rev*. 13: 236-301.
20. Ibrahim AS, Spellberg B, Avanesian V, Fu Y, Edwards JE Jr et al. (2005) *Rhizopus oryzae* adheres to, is phagocytosed by, and damages endothelial cells in vitro. *Infect Immun*. 73: 778-783.
21. Walsh TJ, Gamaletsou MN, McGinnis MR, Hayden RT, Kontoyiannis DP, et al. (2012) Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis). *Clinical Infectious Diseases*. 54: S55-60.
22. Groll A H, N Giri, V Petraitis, R Petraitiene, M Candelario, et al. (2000) Comparative efficacy and distribution of lipid formulations of amphotericin-B B in experimental *Candida albicans* infection of the central nervous system. *J. Infect. Dis*. 182: 274-282.
23. Ibrahim A S, V Avanesian, B Spellberg, J E Edwards (2003) Liposomal amphotericin-BB, and not amphotericin-BB deoxycholate, improves survival of diabetic mice infected with *Rhizopus oryzae*. *Antimicrob. Agents Chemother*. 47: 3343-3344.
24. Gleissner B, A Schilling, I Anagnostopoulou, I Siehl, E Thiel et al. (2004) Improved outcome of zygomycosis in patients with hematological diseases? *Leukemia Lymphoma* 45: 1351-1360.
25. Ibrahim A S, S Klein H Lee, Y Fu, H Waskin, J Edwards, et al. (2000) Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada.
26. Spellberg B, Y Fu, J Edwards Jr, A S Ibrahim. (2005) Combination therapy with amphotericin-B B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. *Antimicrob. Agents Chemother*. 49: 830-832.
27. Eisen DP, J Robson (2004) Complete resolution of pulmonary *Rhizopus oryzae* infection with itraconazole treatment: more evidence of the utility of azoles for zygomycosis. *Mycoses* 47: 159-162.
28. Spellberg B, Edwards J, Ibrahim A (2005) "Novel perspectives on mucormycosis: pathophysiology, presentation, and management". *Clin. Microbiol. Rev*. 18: 556-569.
29. Brizendine KD, Vishin S, Baddley JW (2011) Antifungal prophylaxis in solid organ transplant recipients: external icon. *Expert Rev Anti Infect Ther*. 9: 571-581.
30. Rogers TR, Slavin MA, Donnelly JP (2011) Antifungal prophylaxis during treatment for hematological malignancies: are we there yet? external icon *Br J Haematol*. 153: 681-697.
31. Spellberg B, Ibrahim A, Rolides E, Lewis RE, Lortholary O, et al. (2012) Combination therapy for mucormycosis: why, what, and how?. *Clinical infectious diseases*. 54: S73-8.

Copyright: ©2021 Mukesh Kumar. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.